Alliance Global Partners lowered the firm’s price target on Evogene (EVGN) to $11.25 from $15 and keeps a Buy rating on the shares following the Q3 report. The results were at the lower end of expectations as the Casterra Castor seed revenues are delayed by an extended rain season in Africa, the analyst tells investors in a research note. The firm reduced its Q4 and 2025 forecasts. The next key catalyst remains the revenue ramp for the Castor seed business, adds Alliance.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVGN:
- Evogene price target lowered to $5 from $12 at Lake Street
- Evogene Sees Revenue Growth and Expands AI Collaboration
- Evogene reports Q3 EPS ($1.31) vs. (81c) last year
- EVGN Upcoming Earnings Report: What to Expect?
- Evogene subsidiary Lavie Bio announces commercial expansion of Yalos treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
